PPC
HAE icon

Park Place Capital’s Haemonetics HAE Stock Holding History

Park Place Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-307
Closed -$27.5K – 934
2023
Q3 		$27.5K Hold
307
– – 0.01% 575
2023
Q2 		$26.1K Hold
307
– – 0.01% 605
2023
Q1 		$25.4K Sell
307
-79
-20% -$6.39K 0.01% 603
2022
Q4 		$30K Buy
+386
New +$31K 0.01% 562

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Park Place Capital's HAE Position: Q4 2023 in Review

Park Place Capital sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 307 shares — an estimated $27.5K sold.

Park Place Capital first reported a position in HAE in Q4 2022 and held it in 4 quarters. The position peaked at $30K in Q4 2022. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Park Place Capital reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Park Place Capital sold 307 Haemonetics shares in Q4 2023, an estimated $27.5K.
  • Park Place Capital first reported a position in Haemonetics in Q4 2022 and held it in 4 quarters.
  • Park Place Capital's Haemonetics position peaked at $30K in Q4 2022.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Park Place Capital's 13F filing for Q4 2023, filed 24 Jan 2024.